查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1221052

纖維肌痛症治療的全球市場:風濕性疾病的盛行率上升和並用藥物療法的研究開發的活躍推動增長

Growing Prevalence of Rheumatic Disorders, and Rising R&D on Combination Pharmacological Therapies, are Factors Propelling the Overall Market for Fibromyalgia Treatment
出版日期: | 出版商: Persistence Market Research | 英文 231 Pages | 商品交期: 2-5個工作天內

價格

本報告提供全球纖維肌痛症治療市場相關調查，提供市場動態，各市場區隔及各地區的趨勢，及企業簡介等資訊。

目錄

第1章 摘要整理

第2章 市場概要

  • 市場範圍/分類法
  • 市場定義/範圍/限制
  • 涵蓋與除外

第3章 主要市場趨勢

  • 影響市場的主要趨勢
  • 藥物類別革新/開發趨勢

第4章 主要成功因素

  • 藥物類別採用分析
  • 主要的法規
  • 最近的藥物類別銷售/核准
  • PESTEL分析
  • 開發平台評估
  • 主要的推銷策略:各主要企業
  • 波特分析
  • 價值鏈分析

第5章 市場背景

  • 宏觀經濟要素
  • 預測要素 - 相關性及影響
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會分析

第6章 COVID-19危機分析

  • COVID-19及影響分析
    • 各類藥物
    • 各流通管道
    • 各國
  • 市場情勢(2022年)

第7章 全球纖維肌痛症治療市場需求分析與預測

  • 過去的市場分析
  • 現在及未來市場預測
    • 與前一年同期比較成長趨勢分析

第8章 全球纖維肌痛症治療市場分析與預測:各類藥物

  • 簡介/主要的調查結果
  • 過去的市場分析:各類藥物
  • 現在及未來市場分析與預測:各類藥物
    • 抗憂鬱症藥
    • 抗痙攣藥
    • 肌肉鬆弛劑
    • 止痛藥
  • 市場魅力分析:各類藥物

第9章 全球纖維肌痛症治療市場分析與預測:各流通管道

  • 簡介/主要的調查結果
  • 過去的市場分析:各流通管道
  • 現在及未來市場分析與預測:各流通管道
    • 醫院藥局
    • 藥妝店
    • 零售藥局
    • 線上藥局
  • 市場魅力分析:各流通管道

第10章 全球纖維肌痛症治療市場分析與預測:各地區

  • 簡介
  • 過去的市場分析:各地區
  • 現在及未來市場分析與預測
    • 北美
    • 南美
    • 歐洲
    • 東亞
    • 南亞
    • 大洋洲
    • 中東·非洲
  • 市場魅力分析:各地區

第11章 北美的纖維肌痛症治療市場分析與預測

第12章 南美的纖維肌痛症治療市場分析與預測

第13章 歐洲的纖維肌痛症治療市場分析與預測

第14章 東亞的纖維肌痛症治療市場分析與預測

第15章 南亞的纖維肌痛症治療市場分析與預測

第16章 大洋洲的纖維肌痛症治療市場分析與預測

第17章 中東·非洲的纖維肌痛症治療市場分析與預測

第18章 市場結構分析

  • 市場分析:企業各層級
  • 主要企業的市場佔有率分析
  • 市場影響分析

第19章 競爭分析

  • 競爭儀表板
  • 競爭的詳細資訊
    • FSD Pharma
    • Pfizer, Inc.
    • Eli Lilly and Company
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Johnson & Johnson Services, Inc
    • Sanofi
    • GlaxoSmithKline plc.
    • Bayer AG
    • TONIX Pharmaceuticals Holdings Corp
    • Virios Therapeutics, Inc.
    • Aptinyx Inc.

第20章 前提條件與使用的縮寫

第21章 調查手法

Product Code: PMRREP32455

Fibromyalgia Treatment Market: Scope of the Report

The latest publication by Persistence Market Research on the global fibromyalgia treatment market evaluates the opportunities and current market landscape and provides detailed analysis, and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2023-2033.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for fibromyalgia treatment products and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the fibromyalgia treatment market. Shareholders in the fibromyalgia treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts can leverage insights and information presented in this Persistence Market Research study.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the fibromyalgia treatment market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research's study on the fibromyalgia treatment market offers information divided into three important segments - drug class, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Class

Antidepressants

Venlafaxine

Duloxetine HCl

Milnacipran HCl

Others

Anticonvulsants

Pregabalin

Gabapentin

Others

Muscle Relaxants

Analgesics

Distribution Channel

Hospitals Pharmacies

Drug Stores

Retail Pharmacies

Online Pharmacies

Region

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East and Africa (MEA)

Key Questions Answered in Report:

Which regions will continue to remain the most profitable markets for fibromyalgia treatment over the coming years?

How will changing trends influence the market?

How has the COVID-19 crisis influenced market growth?

How can market players capture the low-hanging opportunities in developed regions?

What are the strategies of stakeholders in the market to shape their position in this landscape?

What are the restraining factors that investors need to be aware of and might tackle while investing in the market?

What are the developmental trends that will influence the market?

How can companies in the fibromyalgia treatment market avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the fibromyalgia treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research's projections on the growth prospects of the fibromyalgia treatment market are more accurate and reliable.

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Drug Class Innovation / Development Trends

4. Key Success Factors

  • 4.1. Drug Class Adoption Analysis
  • 4.2. Key Regulations
  • 4.3. Recent Drug Class launches/ Approvals
  • 4.4. PESTEL Analysis
  • 4.5. Pipeline Assessment
  • 4.6. Key Promotional Strategies, By Key Players
  • 4.7. Porter's Analysis
  • 4.8. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Musculoskeletal Disorder drugs market
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increase in R&D Spending
    • 5.2.2. Growing Disease Prevalence
    • 5.2.3. Cost of Drug Class
    • 5.2.4. Drug Class Features
    • 5.2.5. New Drug Class approvals
    • 5.2.6. Drug Class Pipeline
    • 5.2.7. Changes in Regulatory Policies
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug Class
    • 6.1.2. By Distribution Channel
    • 6.1.3. By Country
  • 6.2. 2022 Market Scenario

7. Global Fibromyalgia Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2016-2022 and Forecast, 2023-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2016-2022
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033, By Drug Class

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2016-2022
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2023-2033
    • 8.3.1. Antidepressants
      • 8.3.1.1. Venlafaxine
      • 8.3.1.2. Duloxetine HCl
      • 8.3.1.3. Milnacipran HCl
      • 8.3.1.4. Others
    • 8.3.2. Anticonvulsants
      • 8.3.2.1. Pregabalin
      • 8.3.2.2. Gabapentin
      • 8.3.2.3. Others
    • 8.3.3. Muscle Relaxants
    • 8.3.4. Analgesics
  • 8.4. Market Attractiveness Analysis By Drug Class

9. Global Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033, By Distribution Channel

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2016-2022
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033
    • 9.3.1. Hospitals Pharmacies
    • 9.3.2. Drug Stores
    • 9.3.3. Retail Pharmacies
    • 9.3.4. Online Pharmacies
  • 9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033, By Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2022
  • 10.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, 2023-2033
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2022
  • 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2023-2033
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Drug Class
    • 11.3.3. By Distribution Channel
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Drug Class
    • 11.4.3. By Distribution Channel
  • 11.5. Market Trends
  • 11.6. Drivers and Restraints - Impact Analysis
  • 11.7. Key Players - Intensity Mapping
  • 11.8. Country Level Analysis & Forecast
    • 11.8.1. U.S. Fibromyalgia Treatment Market Analysis
      • 11.8.1.1. Introduction
      • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.1.2.1. By Drug Class
        • 11.8.1.2.2. By Distribution Channel
    • 11.8.2. Canada Fibromyalgia Treatment Market Analysis
      • 11.8.2.1. Introduction
      • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.2.2.1. By Drug Class
        • 11.8.2.2.2. By Distribution Channel

12. Latin America Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2022
  • 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2023-2033
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Drug Class
    • 12.3.3. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Drug Class
    • 12.4.3. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. Mexico Fibromyalgia Treatment Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Drug Class
        • 12.8.1.2.2. By Distribution Channel
    • 12.8.2. Brazil Fibromyalgia Treatment Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Drug Class
        • 12.8.2.2.2. By Distribution Channel
    • 12.8.3. Argentina Fibromyalgia Treatment Market Analysis
      • 12.8.3.1. Introduction
      • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.3.2.1. By Drug Class
        • 12.8.3.2.2. By Distribution Channel

13. Europe Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2022
  • 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2023-2033
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Drug Class
    • 13.3.3. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug Class
    • 13.4.3. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Germany Fibromyalgia Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug Class
        • 13.8.1.2.2. By Distribution Channel
    • 13.8.2. Italy Fibromyalgia Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug Class
        • 13.8.2.2.2. By Distribution Channel
    • 13.8.3. France Fibromyalgia Treatment Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Drug Class
        • 13.8.3.2.2. By Distribution Channel
    • 13.8.4. U.K. Fibromyalgia Treatment Market Analysis
      • 13.8.4.1. Introduction
      • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.4.2.1. By Drug Class
        • 13.8.4.2.2. By Distribution Channel
    • 13.8.5. Spain Fibromyalgia Treatment Market Analysis
      • 13.8.5.1. Introduction
      • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.5.2.1. By Drug Class
        • 13.8.5.2.2. By Distribution Channel
    • 13.8.6. BENELUX Fibromyalgia Treatment Market Analysis
      • 13.8.6.1. Introduction
      • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.6.2.1. By Drug Class
        • 13.8.6.2.2. By Distribution Channel
    • 13.8.7. Russia Fibromyalgia Treatment Market Analysis
      • 13.8.7.1. Introduction
      • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.7.2.1. By Drug Class
        • 13.8.7.2.2. By Distribution Channel

14. East Asia Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2022
  • 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2023-2033
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Drug Class
    • 14.3.3. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug Class
    • 14.4.3. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Fibromyalgia Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug Class
        • 14.8.1.2.2. By Distribution Channel
    • 14.8.2. Japan Fibromyalgia Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug Class
        • 14.8.2.2.2. By Distribution Channel
    • 14.8.3. South Korea Fibromyalgia Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug Class
        • 14.8.3.2.2. By Distribution Channel

15. South Asia Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2022
  • 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2023-2033
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Drug Class
    • 15.3.3. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug Class
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Fibromyalgia Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug Class
        • 15.8.1.2.2. By Distribution Channel
    • 15.8.2. Indonesia Fibromyalgia Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug Class
        • 15.8.2.2.2. By Distribution Channel
    • 15.8.3. Malaysia Fibromyalgia Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug Class
        • 15.8.3.2.2. By Distribution Channel
    • 15.8.4. Thailand Fibromyalgia Treatment Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug Class
        • 15.8.4.2.2. By Distribution Channel

16. Oceania Fibromyalgia Treatment Market 2016-2023 and Forecast 2023-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2022
  • 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2023-2033
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Drug Class
    • 16.3.1. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug Class
    • 16.4.3. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Australia Fibromyalgia Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug Class
        • 16.8.1.2.2. By Distribution Channel
    • 16.8.2. New Zealand Fibromyalgia Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug Class
        • 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2022
  • 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2023-2033
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkey
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Drug Class
    • 17.3.3. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug Class
    • 17.4.3. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. GCC Countries Fibromyalgia Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug Class
        • 17.8.1.2.2. By Distribution Channel
    • 17.8.2. Turkey Fibromyalgia Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug Class
        • 17.8.2.2.2. By Distribution Channel
    • 17.8.3. South Africa Fibromyalgia Treatment Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug Class
        • 17.8.3.2.2. By Distribution Channel
    • 17.8.4. North Africa Fibromyalgia Treatment Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug Class
        • 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Deep Dive
    • 19.2.1. FSD Pharma
      • 19.2.1.1. Overview
      • 19.2.1.2. Product Portfolio
      • 19.2.1.3. Sales Footprint
      • 19.2.1.4. Key Financials
      • 19.2.1.5. SWOT Analysis
      • 19.2.1.6. Strategy Overview
        • 19.2.1.6.1. Marketing Strategy
        • 19.2.1.6.2. Product Strategy
        • 19.2.1.6.3. Channel Strategy
    • 19.2.2. Pfizer, Inc.
      • 19.2.2.1. Overview
      • 19.2.2.2. Product Portfolio
      • 19.2.2.3. Sales Footprint
      • 19.2.2.4. Key Financials
      • 19.2.2.5. SWOT Analysis
      • 19.2.2.6. Strategy Overview
        • 19.2.2.6.1. Marketing Strategy
        • 19.2.2.6.2. Product Strategy
        • 19.2.2.6.3. Channel Strategy
    • 19.2.3. Eli Lilly and Company
      • 19.2.3.1. Overview
      • 19.2.3.2. Product Portfolio
      • 19.2.3.3. Sales Footprint
      • 19.2.3.4. Key Financials
      • 19.2.3.5. SWOT Analysis
      • 19.2.3.6. Strategy Overview
        • 19.2.3.6.1. Marketing Strategy
        • 19.2.3.6.2. Product Strategy
        • 19.2.3.6.3. Channel Strategy
    • 19.2.4. AbbVie, Inc.
      • 19.2.4.1. Overview
      • 19.2.4.2. Product Portfolio
      • 19.2.4.3. Sales Footprint
      • 19.2.4.4. Key Financials
      • 19.2.4.5. SWOT Analysis
      • 19.2.4.6. Strategy Overview
        • 19.2.4.6.1. Marketing Strategy
        • 19.2.4.6.2. Product Strategy
        • 19.2.4.6.3. Channel Strategy
    • 19.2.5. Teva Pharmaceutical Industries Ltd.
      • 19.2.5.1. Overview
      • 19.2.5.2. Product Portfolio
      • 19.2.5.3. Sales Footprint
      • 19.2.5.4. Key Financials
      • 19.2.5.5. SWOT Analysis
      • 19.2.5.6. Strategy Overview
        • 19.2.5.6.1. Marketing Strategy
        • 19.2.5.6.2. Product Strategy
        • 19.2.5.6.3. Channel Strategy
    • 19.2.6. Johnson & Johnson Services, Inc
      • 19.2.6.1. Overview
      • 19.2.6.2. Product Portfolio
      • 19.2.6.3. Sales Footprint
      • 19.2.6.4. Key Financials
      • 19.2.6.5. SWOT Analysis
      • 19.2.6.6. Strategy Overview
        • 19.2.6.6.1. Marketing Strategy
        • 19.2.6.6.2. Product Strategy
        • 19.2.6.6.3. Channel Strategy
    • 19.2.7. Sanofi
      • 19.2.7.1. Overview
      • 19.2.7.2. Product Portfolio
      • 19.2.7.3. Sales Footprint
      • 19.2.7.4. Key Financials
      • 19.2.7.5. SWOT Analysis
      • 19.2.7.6. Strategy Overview
        • 19.2.7.6.1. Marketing Strategy
        • 19.2.7.6.2. Product Strategy
        • 19.2.7.6.3. Channel Strategy
    • 19.2.8. GlaxoSmithKline plc.
      • 19.2.8.1. Overview
      • 19.2.8.2. Product Portfolio
      • 19.2.8.3. Sales Footprint
      • 19.2.8.4. Key Financials
      • 19.2.8.5. SWOT Analysis
      • 19.2.8.6. Strategy Overview
        • 19.2.8.6.1. Marketing Strategy
        • 19.2.8.6.2. Product Strategy
        • 19.2.8.6.3. Channel Strategy
    • 19.2.9. Bayer AG
      • 19.2.9.1. Overview
      • 19.2.9.2. Product Portfolio
      • 19.2.9.3. Sales Footprint
      • 19.2.9.4. Key Financials
      • 19.2.9.5. SWOT Analysis
      • 19.2.9.6. Strategy Overview
        • 19.2.9.6.1. Marketing Strategy
        • 19.2.9.6.2. Product Strategy
        • 19.2.9.6.3. Channel Strategy
    • 19.2.10. TONIX Pharmaceuticals Holdings Corp
      • 19.2.10.1. Overview
      • 19.2.10.2. Product Portfolio
      • 19.2.10.3. Sales Footprint
      • 19.2.10.4. Key Financials
      • 19.2.10.5. SWOT Analysis
      • 19.2.10.6. Strategy Overview
        • 19.2.10.6.1. Marketing Strategy
        • 19.2.10.6.2. Product Strategy
        • 19.2.10.6.3. Channel Strategy
    • 19.2.11. Virios Therapeutics, Inc.
      • 19.2.11.1. Overview
      • 19.2.11.2. Product Portfolio
      • 19.2.11.3. Sales Footprint
      • 19.2.11.4. Key Financials
      • 19.2.11.5. SWOT Analysis
      • 19.2.11.6. Strategy Overview
        • 19.2.11.6.1. Marketing Strategy
        • 19.2.11.6.2. Product Strategy
        • 19.2.11.6.3. Channel Strategy
    • 19.2.12. Aptinyx Inc.
      • 19.2.12.1. Overview
      • 19.2.12.2. Product Portfolio
      • 19.2.12.3. Sales Footprint
      • 19.2.12.4. Key Financials
      • 19.2.12.5. SWOT Analysis
      • 19.2.12.6. Strategy Overview
        • 19.2.12.6.1. Marketing Strategy
        • 19.2.12.6.2. Product Strategy
        • 19.2.12.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology

List of Tables

  • Table 01: Global Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033 By Drug Class
  • Table 02: Global Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033 By Distribution Channel
  • Table 03: Global Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033 by Region
  • Table 04: North America Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 by Country
  • Table 05: North America Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Drug Class
  • Table 06: North America Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Distribution Channel
  • Table 07: Latin America Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 by Country
  • Table 08: Latin America Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Drug Class
  • Table 09: Latin America Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Distribution Channel
  • Table 10: Europe Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 by Country
  • Table 11: Europe Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Drug Class
  • Table 12: Europe Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033By Distribution Channel
  • Table 13: East Asia Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 by Country
  • Table 14: East Asia Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Drug Class
  • Table 15: East Asia Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Distribution Channel
  • Table 16: South Asia Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 by Country
  • Table 17: South Asia Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Drug Class
  • Table 18: South Asia Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Distribution Channel
  • Table 19: Oceania Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 by Country
  • Table 20: Oceania Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Drug Class
  • Table 21: Oceania Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023-2033By Distribution Channel
  • Table 22: Middle East & Africa Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 by Country
  • Table 23: Middle East & Africa Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022 and Forecast 2023-2033 By Drug Class
  • Table 24: Middle East & Africa Fibromyalgia Treatment Market Analysis 2016-2022 and Forecast 2023- 2033 By Distribution Channel

List of Figures

  • Figure 01: Global Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022
  • Figure 02: Global Fibromyalgia Treatment Market Forecast & Y-o-Y Growth 2023-2033
  • Figure 03: Global Fibromyalgia Treatment Market Absolute $ Opportunity (US$ Mn) Analysis 2022-2033
  • Figure 04: Global Fibromyalgia Treatment Market Value Share (%) Analysis 2023 and 2033 By Drug Class
  • Figure 05: Global Fibromyalgia Treatment Market Y-o-Y Growth (%) Analysis 2022-2033 By Drug Class
  • Figure 06: Global Fibromyalgia Treatment Market Attractiveness Analysis 2023-2033 By Drug Class
  • Figure 07: Global Fibromyalgia Treatment Market Value Share (%) Analysis 2023 and 2033 By Distribution Channel
  • Figure 08: Global Fibromyalgia Treatment Market Y-o-Y Growth (%) Analysis 2022-2033 By Distribution Channel
  • Figure 09: Global Fibromyalgia Treatment Market Attractiveness Analysis 2023-2033 By Distribution Channel
  • Figure 10: Global Fibromyalgia Treatment Market Value Share (%) Analysis 2023 and 2033 by Region
  • Figure 11: Global Fibromyalgia Treatment Market Y-o-Y Growth (%) Analysis 2022-2033 by Region
  • Figure 12: Global Fibromyalgia Treatment Market Attractiveness Analysis 2023-2033 by Region
  • Figure 13: North America Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022
  • Figure 14: North America Fibromyalgia Treatment Market Value (US$ Mn) Forecast 2023-2033
  • Figure 15: North America Fibromyalgia Treatment Market Value Share By Drug Class (2023 E)
  • Figure 16: North America Fibromyalgia Treatment Market Value Share By Distribution Channel (2023 E)
  • Figure 17: North America Fibromyalgia Treatment Market Value Share by Country (2023 E)
  • Figure 18: North America Fibromyalgia Treatment Market Attractiveness Analysis By Drug Class 2023-2033
  • Figure 19: North America Fibromyalgia Treatment Market Attractiveness Analysis by Country 2023-2033
  • Figure 20: U.S. Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 21: Global Vs. U.S. Growth Comparison 2022 - 2033
  • Figure 22: U.S. Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 23: U.S. Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 24: Canada Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 25: Global Vs. Canada. Growth Comparison 2022 - 2033
  • Figure 26: Canada Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 27: Canada Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 28: Latin America Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022
  • Figure 29: Latin America Fibromyalgia Treatment Market Value (US$ Mn) Forecast 2023-2033
  • Figure 30: Latin America Fibromyalgia Treatment Market Value Share By Drug Class (2023 E)
  • Figure 31: Latin America Fibromyalgia Treatment Market Value Share By Distribution Channel (2023 E)
  • Figure 32: Latin America Fibromyalgia Treatment Market Value Share by Country (2023 E)
  • Figure 33: Latin America Fibromyalgia Treatment Market Attractiveness Analysis By Drug Class 2023-2033
  • Figure 34: Latin America Fibromyalgia Treatment Market Attractiveness Analysis By Distribution Channel 2023-2033
  • Figure 35: Latin America Fibromyalgia Treatment Market Attractiveness Analysis by Country 2023-2033
  • Figure 36: Mexico Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 37: Global Vs Mexico Growth Comparison 2022 - 2033
  • Figure 38: Mexico Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 39: Mexico Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 40: Brazil Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 41: Global Vs. Brazil. Growth Comparison 2022 - 2033
  • Figure 42: Brazil Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 43: Brazil Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 44: Argentina Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 45: Global Vs Argentina Growth Comparison 2022 - 2033
  • Figure 46: Argentina Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 47: Argentina Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 48: Europe Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022
  • Figure 49: Europe Fibromyalgia Treatment Market Value (US$ Mn) Forecast 2023-2033
  • Figure 50: Europe Fibromyalgia Treatment Market Value Share By Drug Class (2023 E)
  • Figure 51: Europe Fibromyalgia Treatment Market Value Share By Distribution Channel (2023 E)
  • Figure 52: Europe Fibromyalgia Treatment Market Value Share by Country (2023 E)
  • Figure 53: Europe Fibromyalgia Treatment Market Attractiveness Analysis By Drug Class 2023-2033
  • Figure 54: Europe Fibromyalgia Treatment Market Attractiveness Analysis By Distribution Channel 2023-2033
  • Figure 55: Europe Fibromyalgia Treatment Market Attractiveness Analysis by Country 2023-2033
  • Figure 56: UK Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 57: Global Vs. UK Growth Comparison 2022 - 2033
  • Figure 58: UK Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 59: UK Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 60: Germany Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 61: Global Vs. Germany Growth Comparison 2022 - 2033
  • Figure 62: Germany Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 63: Germany Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 64: Italy Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 65: Global Vs. Italy Growth Comparison 2022 - 2033
  • Figure 66: Italy Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 67: Italy Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 68: France Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 69: Global Vs France Growth Comparison 2022 - 2033
  • Figure 70: France Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 71: France Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 72: Spain Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 73: Global Vs Spain Growth Comparison 2022 - 2033
  • Figure 74: Spain Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 75: Spain Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 76: Russia Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 77: Global Vs Russia Growth Comparison 2022 - 2033
  • Figure 78: Russia Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 79: Russia Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 80: BENELUX Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 81: Global Vs BENELUX Growth Comparison 2022 - 2033
  • Figure 82: BENELUX Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 83: BENELUX Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 84: East Asia Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022
  • Figure 85: East Asia Fibromyalgia Treatment Market Value (US$ Mn) Forecast 2023-2033
  • Figure 86: East Asia Fibromyalgia Treatment Market Value Share By Drug Class (2023 E)
  • Figure 87: East Asia Fibromyalgia Treatment Market Value Share By Distribution Channel (2023 E)
  • Figure 88: East Asia Fibromyalgia Treatment Market Value Share by Country (2023 E)
  • Figure 89: East Asia Fibromyalgia Treatment Market Attractiveness Analysis By Drug Class 2023-2033
  • Figure 90: East Asia Fibromyalgia Treatment Market Attractiveness Analysis By Distribution Channel 2023-2033
  • Figure 91: East Asia Fibromyalgia Treatment Market Attractiveness Analysis by Country 2023-2033
  • Figure 92: China Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 93: Global Vs. China Growth Comparison 2022 - 2033
  • Figure 94: China Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 95: China Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 96: Japan Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 97: Global Vs. Japan Growth Comparison 2022 - 2033
  • Figure 98: Japan Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 99: Japan Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 100: South Korea Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 101: Global Vs South Korea Growth Comparison 2022 - 2033
  • Figure 102: South Korea Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 103: South Korea Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 104: South Asia Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022
  • Figure 105: South Asia Fibromyalgia Treatment Market Value (US$ Mn) Forecast 2023-2033
  • Figure 106: South Asia Fibromyalgia Treatment Market Value Share By Drug Class (2023 E)
  • Figure 107: South Asia Fibromyalgia Treatment Market Value Share By Distribution Channel (2023 E)
  • Figure 108: South Asia Fibromyalgia Treatment Market Value Share by Country (2023 E)
  • Figure 109: South Asia Fibromyalgia Treatment Market Attractiveness Analysis By Drug Class 2023-2033
  • Figure 110: South Asia Fibromyalgia Treatment Market Attractiveness Analysis By Distribution Channel 2023-2033
  • Figure 111: South Asia Fibromyalgia Treatment Market Attractiveness Analysis by Country 2023-2033
  • Figure 112: India Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 113: Global Vs. India Growth Comparison 2022 - 2033
  • Figure 114: India Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 115: India Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 116: Indonesia Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 117: Global Vs. Indonesia Growth Comparison 2022 - 2033
  • Figure 118: Indonesia Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 119: Indonesia Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 120: Malaysia Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 121: Global Vs. Malaysia Growth Comparison 2022 - 2033
  • Figure 122: Malaysia Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 123: Malaysia Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 124: Thailand Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 125: Global Vs. Thailand Growth Comparison 2022 - 2033
  • Figure 126: Thailand Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 127: Thailand Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 128: Oceania Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022
  • Figure 129: Oceania Fibromyalgia Treatment Market Value (US$ Mn) Forecast 2023-2033
  • Figure 130: Oceania Fibromyalgia Treatment Market Value Share By Drug Class (2023 E)
  • Figure 131: Oceania Fibromyalgia Treatment Market Value Share By Distribution Channel (2023 E)
  • Figure 132: Oceania Fibromyalgia Treatment Market Value Share by Country (2023 E)
  • Figure 133: Oceania Fibromyalgia Treatment Market Attractiveness Analysis By Drug Class 2023-2033
  • Figure 134: Oceania Fibromyalgia Treatment Market Attractiveness Analysis By Distribution Channel 2023-2033
  • Figure 135: Oceania Fibromyalgia Treatment Market Attractiveness Analysis by Country 2023-2033
  • Figure 136: Australia Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 137: Global Vs. Australia Growth Comparison 2022 - 2033
  • Figure 138: Australia Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 139: Australia Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 140: New Zealand Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 141: Global Vs New Zealand Growth Comparison 2022 - 2033
  • Figure 142: New Zealand Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 143: New Zealand Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 144: Middle East & Africa Fibromyalgia Treatment Market Value (US$ Mn) Analysis 2016-2022
  • Figure 145: Middle East & Africa Fibromyalgia Treatment Market Value (US$ Mn) Forecast 2023-2033
  • Figure 146: Middle East & Africa Fibromyalgia Treatment Market Value Share By Drug Class (2023 E)
  • Figure 147: Middle East & Africa Fibromyalgia Treatment Market Value Share By Distribution Channel (2023 E)
  • Figure 148: Middle East & Africa Fibromyalgia Treatment Market Value Share by Country (2023 E)
  • Figure 149: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis By Drug Class 2023-2033
  • Figure 150: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis By Distribution Channel 2023-2033
  • Figure 151: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis by Country 2023-2033
  • Figure 152: GCC Countries Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 153: Global Vs GCC Countries Growth Comparison 2022 - 2033
  • Figure 154: GCC Countries Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 155: GCC Countries Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 156: Turkey Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 157: Global Vs. Turkey Growth Comparison 2022 - 2033
  • Figure 158: Turkey Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 159: Turkey Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 160: South Africa Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 161: Global Vs. South Africa Growth Comparison 2022 - 2033
  • Figure 162: South Africa Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 163: South Africa Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033
  • Figure 164: North Africa Fibromyalgia Treatment Market Value Proportion Analysis 2022
  • Figure 165: Global Vs North Africa Growth Comparison 2022 - 2033
  • Figure 166: North Africa Fibromyalgia Treatment Market Share Analysis (%) By Drug Class 2022 & 2033
  • Figure 167: North Africa Fibromyalgia Treatment Market Share Analysis (%) By Distribution Channel 2022 & 2033